US Patent Issued to ONK THERAPEUTICS on Jan. 27 for "Natural killer cells expressing a chimeric antigen receptor that binds CD38" (Irish Inventor)

ALEXANDRIA, Va., Jan. 28 -- United States Patent no. 12,534,536, issued on Jan. 27, was assigned to ONK THERAPEUTICS Ltd. (Galway, Ireland).

"Natural killer cells expressing a chimeric antigen receptor that binds CD38" was invented by Michael Eamon Peter O'Dwyer (Galway, Ireland).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein are engineered natural killer cells that have been modified to express chimeric antigen receptors (CARs). The cells optionally contain other modifications that improve tumor specific cytotoxicity and homing to tumor sites. Also contemplated are methods for using the engineered natural killer cells to treat patients with cancer."

The patent was filed on Aug. 31, 2020, un...